transmembrane protein 14AGenealiases: C6orf73 · PTD011
Q-omics provides the consensus-scored TMEM14A profile across patient tissues and cancer cell-line models. TMEM14A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM14A is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TMEM14A RNA expression shows 19,737 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where TMEM14A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM14A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM14A survival associations across molecular data types. TMEM14A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM14A RNA expression–survival associations across cancer types. High TMEM14A expression shows unfavorable associations in ACC, KICH, BRCA and ESCA, but favorable associations in KIRC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM14A RNA expression.
This table summarizes TMEM14A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM14A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM14A shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, LUAD, COAD and KIRC. The HNSC box plot shows higher TMEM14A RNA expression in tumor versus normal tissue (log2 FC = +1.078, t-test p < 0.001).
This table shows molecular features associated with TMEM14A in patient tissues and cancer cell lines. In patient samples, TMEM14A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM14A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
